| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | A synthetic peptide corresponding to a sequence in the middle region of human CD24 protein was used as the immunogen for the CD24 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
CD24 Antibody is a anti-CD24 Rabbit antibody Polyclonal (rabbit origin) supplied in Antigen affinity purified format. Recommended for workflows such as IHC-P with listed reactivity in Human.
Key elements and design rationale
- Target: CD24
- Antibody details: Rabbit, Polyclonal (rabbit origin), isotype Rabbit IgG
- Format: Antigen affinity purified
- Applications (as listed): IHC-P
Biological background
Structurally, CD24 is a heavily glycosylated protein lacking a transmembrane domain, anchored to the plasma membrane via a GPI linkage. The carbohydrate moieties of CD24 contribute to its interactions with lectins and adhesion molecules, which regulate lymphocyte homing and activation. In the nervous system, CD24 is involved in axon growth and synaptic plasticity, while in the immune system it acts as a costimulatory molecule modulating T cell responses. CD24 engagement can influence B cell maturation, dendritic cell activation, and apoptosis signaling.
The CD24 antibody is widely used in immunology, oncology, and stem cell biology research to study immune signaling, cancer progression, and differentiation. Flow cytometry using this antibody identifies CD24-positive cell populations, while western blot analysis detects the mature glycoprotein at approximately 35-40 kilodaltons, with size variability due to glycosylation. Immunohistochemistry reveals membrane staining in lymphoid tissues and various carcinomas.
In cancer research, CD24 has emerged as a key marker of tumor-initiating cells and metastasis. Overexpression is associated with aggressive tumor phenotypes in breast, ovarian, and colorectal cancers, where CD24 promotes cell adhesion to P-selectin on platelets and endothelial cells, aiding metastatic spread. Conversely, CD24 expression can modulate immune responses by interacting with Siglec-10, inhibiting innate immune activation. The CD24 antibody is an essential tool for investigating immune regulation, tumor biology, and cell surface glycoprotein signaling.
Research relevance and current trends
- Connecting protein-level changes to phenotype using orthogonal readouts (genetic perturbation, transcriptomics, imaging).
- Considering isoforms and post-translational regulation when interpreting protein-level changes.
- Comparing results across species and model systems with matched controls.
Common research applications
- Immunohistochemistry: map target signal in tissue context and compare regions/phenotypes.
Interpret changes in signal alongside appropriate controls and, when relevant, in parallel with total-protein or pathway readouts.
Notes for experimental interpretation
- Signal can reflect expression level, isoform composition, and post-translational state; interpret results in the context of your model system and stimuli.
- Species differences and sample matrices can influence epitope recognition; prioritize matched controls and orthogonal confirmation when feasible.
Antibody notes: Polyclonal antibodies recognize multiple epitopes, which can broaden the epitope footprint and may increase sensitivity in some contexts.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
